Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merus N.V. CS
(NQ:
MRUS
)
50.99
+0.51 (+1.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merus N.V. CS
< Previous
1
2
Next >
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
October 06, 2023
From
Merus N.V.
Via
GlobeNewswire
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
September 26, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The...
Via
FinancialNewsMedia
Merus to Participate in Upcoming Investor Conferences
August 31, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Pricing of Public Offering of Common Shares
August 09, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
August 09, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
August 07, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
July 28, 2023
From
Merus N.V.
Via
GlobeNewswire
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
July 05, 2023
From
Merus N.V.
Via
GlobeNewswire
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
June 29, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
June 15, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
May 31, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
May 04, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
April 17, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
April 14, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
April 14, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
March 14, 2023
Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
March 14, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
February 28, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
February 01, 2023
From
Merus N.V.
Via
GlobeNewswire
CORRECTING and REPLACING --Merus Provides 2023 Outlook
January 09, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Provides 2023 Outlook
January 08, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
November 09, 2022
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Third Quarter and Provides Business Update
November 03, 2022
From
Merus N.V.
Via
GlobeNewswire
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
October 26, 2022
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
October 12, 2022
From
Merus N.V.
Via
GlobeNewswire
Promising Developments in Breast Cancer Treatments Ahead in 2022
January 12, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...
Via
FinancialNewsMedia
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.